Related Experiment Video
Updated: Jun 7, 2026

Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
VAV3 is associated with atherosclerosis and ox-LDL-induced endothelial dysfunctional remodeling
Guorong Wang1, Chen Pu1, Qing Li2
1Department of Vascular Surgery, The First Affiliated Hospital, Nanchang University, Nanchang, 330006, Jiangxi, China.
Insights
VAV3 protein is upregulated in atherosclerosis, promoting abnormal endothelial cell proliferation, lipid deposition, and inflammation. Reducing VAV3 may reverse these detrimental effects, offering potential therapeutic avenues for vascular disease.
Area of Science:
- Cardiovascular Biology
- Molecular Pathology
- Immunology
Background:
- Atherosclerosis, a key driver of ischemic stroke, involves intricate immune and metabolic dysregulation.
- The precise role of VAV3, a Rho guanine nucleotide exchange factor, in vascular pathology is not well understood.
Purpose of the Study:
- To investigate the function and underlying mechanisms of VAV3 in the context of atherosclerosis.
- To explore VAV3's involvement in immune-metabolic dysregulation within vascular tissues.
Main Methods:
- Analysis of transcriptomic datasets (GSE43292, GSE28829) using WGCNA and machine learning (Boruta, LASSO) to identify key genes.
- Functional studies in ox-LDL-stimulated human umbilical vein endothelial cells (HUVECs) with VAV3 manipulation (overexpression/knockdown).
- In vivo validation in high-fat diet-fed APOE knockout mice to assess atherosclerotic lesion development.
Main Results:
- Integrated analysis revealed immune activation and metabolic reprogramming in atherosclerotic plaques, with VAV3 identified as a candidate signature.
- VAV3 overexpression in HUVECs promoted proliferation, migration, calcium accumulation, and lipid deposition, while reducing apoptosis.
- VAV3 knockdown reversed these effects, suggesting its role in maladaptive endothelial remodeling and NF-κB pathway activation.
Conclusions:
- VAV3 upregulation in atherosclerosis contributes to ox-LDL-induced endothelial dysfunction, characterized by abnormal proliferation, apoptosis resistance, and inflammation.
- Further research is needed to confirm VAV3's clinical diagnostic value, therapeutic potential, and in vivo causal role in atherosclerosis.
Background:
Atherosclerosis is a major cause of ischemic stroke and is characterized by complex immune-metabolic dysregulation. VAV3, a Rho guanine nucleotide exchange factor, regulates multiple cellular processes, but its role in vascular pathology remains unclear. This study aimed to explore the function and mechanism of VAV3 in atherosclerosis.
Methods:
Transcriptomic datasets (GSE43292 and GSE28829) were analyzed to identify differentially expressed genes and disease-associated co-expression modules using weighted gene co-expression network analysis (WGCNA). The Boruta and LASSO algorithms were applied to screen for disease-associated signatures. Functional validation was performed in ox-LDL-stimulated HUVECs using VAV3 gain- and loss-of-function approaches. Assessments included cell proliferation, apoptosis, intracellular calcium accumulation, migration, lipid deposition, inflammatory factor secretion, and NF-κB pathway activation. In vivo validation was conducted in high-fat diet-fed APOE-/- mice.
Results:
Integrated transcriptomic analysis revealed concurrent immune activation and metabolic reprogramming in carotid plaques. WGCNA identified the MEgreen module as highly associated with atherosclerosis, and machine learning analyses selected CCR1 and VAV3 as public-dataset-derived candidate molecular signatures. In APOE-/- mice, atherosclerotic lesions showed increased lipid deposition, elevated inflammatory mediators, and enhanced VAV3 expression. In ox-LDL-treated HUVECs, VAV3 overexpression further enhanced cell viability, proliferation, and migration, reduced apoptosis, and increased intracellular calcium accumulation and lipid deposition, indicating a shift toward an abnormal proliferative and apoptosis-resistant endothelial phenotype. In contrast, VAV3 knockdown attenuated these ox-LDL-induced abnormal changes and partially restored the cellular phenotype toward the control state. VAV3 modulation also altered GRB2 expression and p65 phosphorylation, accompanied by changes in IL-6, TNF-α, CRP, and Lp-PLA2 secretion. Co-IP further suggested an association between GRB2 and p-P65. These findings indicate that VAV3 may be associated with maladaptive endothelial remodeling and NF-κB-related inflammatory activation under ox-LDL stimulation.
Conclusion:
VAV3 is upregulated in atherosclerotic lesions and may contribute to ox-LDL-induced maladaptive endothelial remodeling, characterized by abnormal proliferation, apoptosis resistance, calcium accumulation, lipid deposition, and inflammatory activation. However, its clinical diagnostic value, therapeutic feasibility, and causal role in vivo require further validation.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Coronary Artery Disease III: Clinical Manifestations
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Coronary Artery Disease I: Introduction